Combined therapeutic effects of fluorouracil (5-FU) and 188Re-liposome in C26 colonic peritoneal carcinomatosis mice

Objectives In this study, we combined the clinical first-line drug Fluorouracil (5-FU) and 188Re-liposomes in the C26 colon carcinoma peritoneal metastasis mice model. 5-FU has been considered having not only the antineoplastic property but also as a radiosensitizer. Thus, we proposed that the combination of 5-FU and 188Re-liposomes will enhance the therapeutic effect.

Methods Colon carcinoma peritoneal metastatic BALB/c mice were intraperitoneal (i.p) administrated with 188Re-liposomes and 5-FU. For the combination therapy, 5-FU was administrated two days before the treatment of 188Re-liposomes. The survival time of mice after respectively treating with 188Re-liposomes, fluorouracil (5-FU), and 188Re-liposomes combined with 5-FU were evaluated and compared.

Results The results showed that 188Re-liposomes combined with 5-FU attained a longer life span in tumor-bearing mice than only chemotherapeutics of 5-FU and radiotherapeutics of 188Re-liposomes did.

Conclusions The combination of 5-FU will enhance the therapeutic effect of 188Re-liposomes. This information will provide the ideal therapeutic strategy of the 188Re-liposomes in clinical application.